Enzymatica appoints Sana Alajmovic as new CEO

Ella Day | August 12, 2025 | Appointment | Research and Development Corporate, Enzymatica, Infections and infestations 

The board of directors of Enzymatica has appointed Sana Alajmovic as chief executive officer, succeeding Claus Egstrand. Egstrand will step down from his role and will then be nominated to join the company’s board of directors.

Alajmovic is currently the co-founder and CEO of Sigrid Therapeutics, a healthtech company specialising in chronic lifestyle diseases. She has extensive experience in business development and leadership within the life sciences sector, with a record in commercialising research and forming strategic partnerships with international pharma and consumer health companies.

Bengt Baron, chairman of the board, said: “Sana Alajmovic is the perfect match for Enzymatica. Her background in life sciences, strong drive and proven commercial acumen makes her well suited to lead the company in the next phase.”

Advertisement

Alajmovic has received multiple awards for her entrepreneurship and leadership, including Sweden’s Most Important Female Founder by Dagens Industri in 2021 and Female Leader of the Future by Ledarna in 2020 and 2021. She has also been listed among the world’s Top Life Sciences Innovators Under 40.  

Commenting on her appointment, Alajmovic stated: “As the new CEO of Enzymatica, my focus is to lead the company into its next phase of growth.”

She will assume her position by 31 January 2026. Enzymatica, based in Lund, Sweden, develops and markets products for the treatment and alleviation of upper airway infections and symptoms.

Ella Day

12/8/25

The Pharmafile Brief

This article featured in: September 2025 – The Pharmafile Brief

Related Content

No items found
The Gateway to Local Adoption Series

Latest content